Anti-metastasis efficacy and safety of non-anticoagulant heparin derivative versus low molecular weight heparin in surgical pancreatic cancer models

Alyahya,Reem; Sudha,Thangirala; Racz,Michael; Stain,Steven C.; Mousa,Shaker A.

doi:10.3892/ijo.2014.2803

Anti-metastasis efficacy and safety of non-anticoagulant heparin derivative versus low molecular weight heparin in surgical pancreatic cancer models

Authors:
- Reem Alyahya
- Thangirala Sudha
- Michael Racz
- Steven C. Stain
- Shaker A. Mousa
View Affiliations

Affiliations: The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA, Department of Basic and Social Sciences, Albany College of Pharmacy and Health Sciences, Albany, NY, USA, Department of Surgery, Albany Medical College, Albany, NY, USA
Published online on: December 19, 2014 https://doi.org/10.3892/ijo.2014.2803
Pages: 1225-1231

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Heparin and its derivatives are known to attenuate cancer metastasis in preclinical models, but have not been used clinically due to adverse bleeding effects. This study compared the efficacy of S-NACH (a sulfated non-anticoagulant heparin) versus tinzaparin (a low molecular weight heparin) in inhibiting metastasis of a growing primary tumor and following surgical excision of primary tumor in a pancreatic cancer mouse model. The efficacy of S-NACH versus tinzaparin on metastasis of the primary tumor was evaluated in each experiment using IVIS imaging. Athymic female mice were treated with S-NACH or tinzaparin, and 30 min later luciferase-transfected pancreatic cancer cells (Mpanc96) were implanted into the spleen; treatment was continued daily until termination. Next we studied the effect of S-NACH versus tinzaparin on metastasis after surgical excision of the primary tumor after 3 weeks of daily treatment with S-NACH or tinzaparin. S-NACH reduced surgically induced metastasis (p<0.01) and tumor recurrence (p<0.05) relative to control. Histopathological studies demonstrated significant increase in tumor necrosis mediated by S-NACH and to lesser extent by tinzaparin as compared to control group. Furthermore, either S-NACH or tinzaparin upregulated the expression of the junctional adhesion molecule E-cadherin in pancreatic cancer cells where its low expression enhances cancer cell migration and invasion. In terms of bleeding time (BT), S-NACH did not affect BT as compared to tinzaparin, which doubled BT. These data suggest that S-NACH is an effective and safe anti-metastatic agent and warrants further clinical evaluation.

View Figures

View References

1	Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
2	Chambers AF, Groom AC and MacDonald IC: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2:563–572. 2002. View Article : Google Scholar : PubMed/NCBI
3	Sener SF, Fremgen A, Menck HR and Winchester DP: Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer Database. J Am Coll Surg. 189:1–7. 1999. View Article : Google Scholar : PubMed/NCBI
4	Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM and Varki A: Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA. 98:3352–3357. 2001. View Article : Google Scholar : PubMed/NCBI
5	Stone JP and Wagner DD: P-selectin mediates adhesion of platelets to neuroblastoma and small cell lung cancer. J Clin Invest. 92:804–813. 1993. View Article : Google Scholar : PubMed/NCBI
6	Mannori G, Crottet P, Cecconi O, et al: Differential colon cancer cell adhesion to E-, P-, and L-selectin: role of mucin-type glycoproteins. Cancer Res. 55:4425–4431. 1995.PubMed/NCBI
7	Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ and Bevilacqua MP: Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood. 82:3253–3258. 1993.PubMed/NCBI
8	Koenig A, Norgard-Sumnicht K, Linhardt R and Varki A: Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest. 101:877–889. 1998. View Article : Google Scholar : PubMed/NCBI
9	Zacharski LR and Loynes JT: The heparins and cancer. Curr Opin Pulm Med. 8:379–382. 2002. View Article : Google Scholar : PubMed/NCBI
10	Kasthuri RS, Taubman MB and Mackman N: Role of tissue factor in cancer. J Clin Oncol. 27:4834–4838. 2009. View Article : Google Scholar : PubMed/NCBI
11	Capila I and Linhardt RJ: Heparin-protein interactions. Angew Chem Int Ed Engl. 41:391–412. 2002. View Article : Google Scholar : PubMed/NCBI
12	Kuderer NM, Khorana AA, Lyman GH and Francis CW: A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer. 110:1149–1161. 2007. View Article : Google Scholar : PubMed/NCBI
13	Mousa SA: Oxidized heparin fractions and their use in inhibiting angiogenesis. US patent 8,071,569. 2011:December 06–2011
14	Lapierre F, Holme K, Lam L, et al: Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties. Glycobiology. 6:355–366. 1996. View Article : Google Scholar : PubMed/NCBI
15	Sudha T, Phillips P, Kanaan C, Linhardt RJ, Borsig L and Mousa SA: Inhibitory effect of non-anticoagulant heparin (S-NACH) on pancreatic cancer cell adhesion and metastasis in human umbilical cord vessel segment and in mouse model. Clin Exp Metastasis. 29:431–439. 2012. View Article : Google Scholar : PubMed/NCBI
16	van der Bij GJ, Oosterling SJ, Beelen RH, Meijer S, Coffey JC and van Egmond M: The perioperative period is an underutilized window of therapeutic opportunity in patients with colorectal cancer. Ann Surg. 249:727–734. 2009. View Article : Google Scholar : PubMed/NCBI
17	Kakkar A, Hedges R, Williamson R and Kakkar V: Perioperative heparin-therapy inhibits late death from metastatic cancer. Int J Oncol. 6:885–888. 1995.PubMed/NCBI
18	von Tempelhoff GF, Harenberg J, Niemann F, Hommel G, Kirkpatrick CJ and Heilmann L: Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial. Int J Oncol. 16:815–824. 2000.PubMed/NCBI
19	Lim E, Modi KD and Kim J: In vivo bioluminescent imaging of mammary tumors using IVIS spectrum. J Vis Exp. 26:12102009.PubMed/NCBI
20	Dejana E, Callioni A, Quintana A and de Gaetano G: Bleeding time in laboratory animals. II - A comparison of different assay conditions in rats. Thromb Res. 15:191–197. 1979. View Article : Google Scholar : PubMed/NCBI
21	Alshaiban A, Muralidharan-Chari V, Nepo A and Mousa SA: Modulation of sickle red blood cell adhesion and its associated changes in biomarkers by sulfated non-anticoagulant heparin derivative. Clin Appl Thromb Hemost. (In press).
22	Gasic GJ, Gasic TB and Stewart CC: Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA. 61:46–52. 1968. View Article : Google Scholar : PubMed/NCBI
23	Kim YJ, Borsig L, Varki NM and Varki A: P-selectin deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci USA. 95:9325–9330. 1998. View Article : Google Scholar : PubMed/NCBI
24	Mousa SA, Linhardt R, Francis JL and Amirkhosravi A: Antimetastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. Thromb Haemost. 96:816–821. 2006.PubMed/NCBI
25	Kragh M, Binderup L, Vig Hjarnaa PJ, Bramm E, Johansen KB and Frimundt Petersen C: Non-anti-coagulant heparin inhibits metastasis but not primary tumor growth. Oncol Rep. 14:99–104. 2005.PubMed/NCBI
26	Bacac M and Stamenkovic I: Metastatic cancer cell. Annu Rev Pathol. 3:221–247. 2008. View Article : Google Scholar : PubMed/NCBI
27	Kopfstein L and Christofori G: Metastasis: cell-autonomous mechanisms versus contributions by the tumor microenvironment. Cell Mol Life Sci. 63:449–468. 2006. View Article : Google Scholar : PubMed/NCBI
28	Achen MG, Mann GB and Stacker SA: Targeting lymphangiogenesis to prevent tumour metastasis. Br J Cancer. 94:1355–1360. 2006. View Article : Google Scholar : PubMed/NCBI
29	Ito S, Nakanishi H, Hirai T, et al: Quantitative detection of CEA expressing free tumor cells in the peripheral blood of colorectal cancer patients during surgery with real-time RT-PCR on a LightCycler. Cancer Lett. 183:195–203. 2002. View Article : Google Scholar : PubMed/NCBI
30	Wang F, Sloss C, Zhang X, Lee SW and Cusack JC: Membrane-bound heparin-binding epidermal growth factor like growth factor regulates E-cadherin expression in pancreatic carcinoma cells. Cancer Res. 67:8486–8493. 2007. View Article : Google Scholar : PubMed/NCBI
31	Phillips PG, Yalcin M, Cui H, et al: Increased tumor uptake of chemotherapeutics and improved chemoresponse by novel non-anticoagulant low molecular weight heparin. Anticancer Res. 31:411–419. 2011.PubMed/NCBI
32	Lebeau B, Baud M, Masanes MJ, Febvre M, Mokhtari T and Chouaid C: Optimization of small-cell lung cancer chemotherapy with heparin: a comprehensive retrospective study of 239 patients treated in a single specialized center. Chemotherapy. 57:253–258. 2011. View Article : Google Scholar : PubMed/NCBI
33	Klerk CP, Smorenburg SM, Otten HM, et al: The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 23:2130–2135. 2005. View Article : Google Scholar : PubMed/NCBI
34	Lebeau B, Chastang C, Brechot JM, et al: Subcutaneous heparin treatment increases survival in small cell lung cancer. ‘Petites Cellules’ Group. Cancer. 74:38–45. 1994. View Article : Google Scholar : PubMed/NCBI
35	Mousa SA and Petersen LJ: Anti-cancer properties of low-molecular-weight heparin: preclinical evidence. Thromb Haemost. 102:258–267. 2009.PubMed/NCBI
36	Mousa SA: Comparative pharmacodynamic assessment of the antiangiogenesis activity of heparin and low-molecular-weight heparin fractions: structure-function relationship. Clin Appl Thromb Hemost. 19:48–54. 2013. View Article : Google Scholar
37	Yu CJ, Ye SJ, Feng ZH, et al: Effect of Fraxiparine, a type of low molecular weight heparin, on the invasion and metastasis of lung adenocarcinoma A549 cells. Oncol Lett. 1:755–760. 2010.PubMed/NCBI
38	Ilan N, Elkin M and Vlodavsky I: Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol. 38:2018–2039. 2006. View Article : Google Scholar : PubMed/NCBI